Spiro-piperidine ureas blend opioid agonism and TRPV1 blockade to ease pain with fewer liabilities
- Pharmacophores of known TRPV1 antagonists and fentanyl-type MOR agonists were merged into two spiro[indoline-3,4'-piperidine] urea series, followed by SAR exploration.
- Lead compound 8m combined potent TRPV1 antagonism with strong MOR agonism and showed dose-dependent efficacy in formalin and capsaicin pain models.
- In mice it avoided the hyperthermia seen with a TRPV1 antagonist and caused little tolerance on repeated dosing versus morphine.
- Docking and molecular dynamics suggest stable binding to both targets via hydrogen, halogen and hydrophobic contacts.
💡 Points Based on the abstract
Fusing a fentanyl-type MOR pharmacophore with a TRPV1 antagonist scaffold risks a big, lipophilic molecule, so I would check ligand efficiency, CNS exposure and hERG early. The tolerance and hyperthermia claims need matched-exposure comparators and a MOR signaling readout (G-protein vs arrestin bias). Next step: selectivity against DOR/KOR.